Sulanemadlin (development code ALRN-6924) is an experimental drug for the treatment of cancer.

[1] It is under development by Aileron Therapeutics, and has been studied in clinical trials for myelodysplastic syndrome and acute myeloid leukemia.

[2] Sulanemadlin is a stapled peptide that mimics the N-terminal domain of p53, a tumor suppressor protein.

As such, it binds to MDM2 and MDMX, leading to tumor cell apoptosis.

[3] Sulanemadlin is notable as the first stapled peptide, a novel pharmaceutical strategy, to enter clinical trials.